2006
DOI: 10.1007/s00280-006-0193-x View full text |Buy / Rent full text
|
|

Abstract: The combination of nedaplatin and 5-FU with radiation is a feasible regimen that shows promising antitumor activity with an acceptable safety profile in patients with esophageal cancer.

Help me understand this report

Search citation statements

Order By: Relevance
Select...
3
1
1
0
14
0

Year Published

2010
2010
2016
2016

Publication Types

Select...
5

Relationship

1
4

Authors

Journals

0
14
0
Order By: Relevance
“…Table 1 showed the basic characteristics of patients included in this review following the chronological order. [4][5][6][7][11][12][13][14][16][17][18][19][20][21][22][23][24][25][26][27][28][29] It should be pointed out that a total of 4 reports were interrelated with RTOG 85-01. To avoid repeated computation, we consolidated and marked these reports as RTOG 85-01.…”
Section: Methodological Issues and Basic Characteristics Of Included mentioning
Create an account to read the remaining citation statements from this report. You will also get access to:
  • Search over 1.2b+ citation statments to see what is being said about any topic in the research literature
  • Advanced Search to find publications that support or contrast your research
  • Citation reports and visualizations to easily see what publications are saying about each other
  • Browser extension to see Smart Citations wherever you read research
  • Dashboards to evaluate and keep track of groups of publications
  • Alerts to stay on top of citations as they happen
  • Automated reference checks to make sure you are citing reliable research in your manuscripts
  • 14 day free preview of our premium features.

Trusted by researchers and organizations around the world

Over 130,000 students researchers, and industry experts at use scite

See what students are saying

rupbmjkragerfmgwileyiopcupepmcmbcthiemesagefrontiersapsiucrarxivemeralduhksmucshluniversity-of-gavle
“…Table 1 showed the basic characteristics of patients included in this review following the chronological order. [4][5][6][7][11][12][13][14][16][17][18][19][20][21][22][23][24][25][26][27][28][29] It should be pointed out that a total of 4 reports were interrelated with RTOG 85-01. To avoid repeated computation, we consolidated and marked these reports as RTOG 85-01.…”
Section: Methodological Issues and Basic Characteristics Of Included mentioning
“…Chemotherapy (Table 1) Fifty-six of patients received concurrent chemoradiotherapy containing the protracted 5-FU 400 mg/m 2 on days 1-5 and on days 8-12 combined with nedaplatin 40-60 mg/m 2 on days 1 and 8, repeated twice every 3 weeks, with concurrent radiotherapy 60 Gy in 30 fractions over 6 weeks [11]. Among twenty of patients, chemotherapy consisted of protracted 5-FU 400 mg/m 2 on days 1-5 and 29-33 combined with CDDP 40 mg/m 2 on days 1 and 29 with concurrent radiation therapy.…”
Section: Eligibility Criteriamentioning
“…An in vitro investigation demonstrated that nedaplatin in combination with irradiation is highly effective for cervical cancer [12]. Although the preliminary data from clinical studies of the use of nedaplatin-based CCRT in patients with head and neck or esophageal cancer has been reported [13], however, the clinical experience with this agent in the setting of CCRT for cervical cancer patients is limited. As shown in Table 1, the use of concurrent weekly nedaplatin in patients with invasive cervical cancer in the setting of definitive radiotherapy was investigated in two Phase I [14, 15], two Phase II [16, 17] studies, and one retrospective study [18]; however, in the setting of adjuvant radiotherapy, nedaplatin-based CCRT has only been evaluated in one Phase I [19] and two retrospective studies [20, 21].…”
Section: Introductionmentioning